DivestmentJul 15, 2026, 07:31 AM
Senti Biosciences Holdings Divests SENTI-202 Pipeline for $60M CVR
AI Summary
Senti Biosciences Holdings, Inc. announced a strategic transaction to divest its Gene-Circuit-enabled pipeline, including SENTI-202, to a newly formed private biotechnology company (NewCo). In exchange, SBH will receive a Contingent Value Right (CVR) providing up to $60 million in milestone payments tied to the future success of SENTI-202. This move allows SBH to sharpen its focus on its Regulator Dial platform and advance early-stage programs for Rett Syndrome and solid tumors.
Key Highlights
- Senti Biosciences Holdings divests Gene-Circuit-enabled pipeline, including SENTI-202, to NewCo.
- SBH to receive a Contingent Value Right (CVR) for up to $60 million in milestone payments.
- CVR includes $10 million for SENTI-202 BLA filing, $20 million for FDA approval.
- CVR includes $30 million upon achieving $200 million in cumulative net sales of SENTI-202.
- SBH will focus on its Regulator Dial platform, including Rett Syndrome and TILs programs.
- SENTI-202 has FDA RMAT designation and showed durable MRD-negative responses in Phase 1 trial.
- Transaction is subject to customary closing conditions, including shareholder approval.
Price Impact
More from SNTI